Big Pharma Could Take Notice of Nuvilex Inc.
(firmenpresse) - BALTIMORE, MD -- (Marketwired) -- 05/16/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, posits that given its current stage of clinical development it is possible that (OTCQB: NVLX) may eventually attract the interest of large pharmaceutical firms seeking to gain access to its highly efficacious and proprietary technology platform. Nuvilex Inc. (OTCQB: NVLX) is an international firm with a live-cell encapsulation technology initially directed to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
Any arrangement typically begins with a lengthy due diligence process with no guarantees that anything material arises from such due diligence. Still, it is not uncommon that the process results in some form of partnership or collaboration. These collaborations often contain an agreement to assist in funding future research and development, a royalty arrangement should development lead to regulatory approval, and occasionally lead to a direct investment in the targeted company itself.
While many companies enter Phase III clinical trials without a partner, this prospective event is relevant to companies like Nuvilex Inc. (OTCQB: NVLX) since it is not uncommon for collaborative relationships to be formalized ahead of a Phase III clinical trial.
Additional detail regarding the structure of biotechnology collaboration relationships as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting .
Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .
(OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1228131
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Venture Capital
Anmerkungen:
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Big Pharma Could Take Notice of Nuvilex Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Goldman Small Cap Research, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
